Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...

EPS and revenue topped estimates, but analysts cite Medicare changes and MS declines as headwinds. Leqembi and Skyclarys remain key growth drivers.

Environmental monitoring is the repeated measurement of physical, chemical and biological variables in order to study environmental changes, particularly those arising from human activities.

The European review saga of Eisai and Biogen’s Alzheimer’s disease med Leqembi also got a CHMP update, with the agency agreeing to consider the European Commission’s request to consider ...

Biogen and Eisai have hit another bump in their quest to win European regulatory approval of their Alzheimer's drug Leqembi. The companies on Friday said the European Commission has asked the ...

The U.S. Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27. Previously, the label called for biweekly IV dosing. The new ...

EMA approval of the Alzheimer’s disease therapy Leqembi (lecanemab) has stalled once again, after the European Commission did not as usual nod through the agency’s recommendation, but told it to ...

Today, a brief rundown of news involving Novartis and AbbVie, as well as updates from Biogen, Merck & Co. and Sanofi that you may have missed. Pioneers like Alnylam Pharmaceuticals have led the RNA ...

Find out what it's like to undergo a Magnetic Resonance Imaging scan, commonly known as an MRI scan, from our short video. Magnetic Resonance Imaging (MRI) scans are used to acquire detailed images of ...

The US Food and Drug Administration has approved monthly maintenance dosing for Japan’s Eisai and partner Biogen’s Alzheimer’s drug Leqembi ... to undergo monitoring with scans.

What is the Previous and Anticipated Market Size and CAGR of the Leqembi Global Market? The growth of the leqembi market has been remarkably robust over the recent years, exhibiting HCAGR of XX%.

Lipid therapy decreases plaque inflammation and neovascularization as assessed by dynamic contrast-enhanced MRI. Future Perspective of Monitoring Lipid Therapy Using MRI 3D sequences lead to ...